Health Care Related Organization
Highlander Health: Revolutionizing Clinical Research with Integrated Solutions
Highlander Health, clinical research, personalized healthcare, evidence generation, technology enablement, Amy Abernethy, Brad Hirsch, Verily, FDA.
GSK to Close UK Antibiotic Factory in Ulverston Following Sandoz Contract Termination
GSK, Ulverston, antibiotic factory, Sandoz contract, closure, job losses
AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms
AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study
WHO Publishes First Guidance to Combat Antibiotic Pollution from Manufacturing
WHO, antibiotic pollution, antimicrobial resistance (AMR), wastewater management, solid waste management, pharmaceutical manufacturing, environmental health
Candid Therapeutics Launches with $370 Million Funding, Aims to Revolutionize T Cell Engager Market for Autoimmune Diseases
Candid Therapeutics, T Cell Engager, Autoimmune Diseases, Biotech Funding, Ken Song, Pharmaceutical Industry
Biopharma Layoff Tracker 2024: Industry Continues to Downsize Amid Economic Uncertainty
Biopharma layoffs, 2024 layoffs, Pharmaceutical industry downsizing, Biotech industry trends, Economic uncertainty
BIOSECURE Act Clears House Hurdle, Heads to Senate for Vote on Restricting Chinese Biotech Ties
BIOSECURE Act, House of Representatives, Senate Vote, Chinese Biotech Companies, National Security Risks, U.S. Pharmaceutical Industry, Biotechnology Innovation, Drug Supply Chain
Eli Lilly Expands AI Capabilities with $409M Genetic Leap Partnership
Eli Lilly, AI, Genetic Leap, drug discovery, RNA specialist, pharmaceutical industry
Eli Lilly Appoints Insider Lucas Montarce as Chief Financial Officer Amid Rising Demand for Weight Loss Drugs
Eli Lilly, Lucas Montarce, CFO, weight loss drugs, Mounjaro, Zepbound, pharmaceutical industry, leadership transition
AstraZeneca Refines NSCLC Treatment Strategies with Biomarker-Driven Approaches
NSCLC, biomarkers, targeted therapy, immunotherapy, AstraZeneca, lung cancer treatment